Drug company shenanigans: narcolepsy drug
I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare ). Based on an article by Rebecca Robbins of the New York Times, who has written several articles on drug company excesses As background, this will be my 42 nd such blog: for the array, see https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans Th e drug company approach this time to extending their patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB) -- the drug actually has a pretty